帕博利珠单抗辅助治疗透明细胞肾细胞癌:KEYNOTE-564 III期研究五年结果
KEYNOTE-564研究纳入994例术后复发风险增高的透明细胞肾细胞癌患者,随机接受帕博利珠单抗200 mg每3周或安慰剂治疗≤17个周期。中位随访70个月,帕博利珠单抗较安慰剂显著改善无病生存(HR 0.71,95%CI 0.59-0.86)和总生存(HR 0.66,95%CI 0.48-0.90),5年DFS率60.9% vs 52.2%,5年OS率87.7% vs 82.3%,安全性与此前分析一致。
要点
- 帕博利珠单抗辅助治疗显著改善复发风险增高的ccRCC患者DFS(HR 0.71)和OS(HR 0.66)。
- 5年DFS率60.9% vs 52.2%,5年OS率87.7% vs 82.3%,中位DFS未达到 vs 68个月。
- DFS和OS获益在关键亚组中一致,安全性与此前分析基本不变。
核心结论
- 中位随访70个月,帕博利珠单抗辅助治疗在复发风险增高的ccRCC中显示持续DFS和OS获益,安全性与此前分析一致,继续支持其应用。
研究设计与样本
- 随机、III期KEYNOTE-564研究(NCT03142334),纳入994例复发风险增高的ccRCC成人患者,1:1随机接受帕博利珠单抗200 mg或安慰剂每3周,≤17个周期(约1年)。
- 主要终点为研究者评估的DFS,关键次要终点为OS,安全性为次要终点;本次为第四次预设 interim 分析,最短随访5年。
主要发现
- 帕博利珠单抗较安慰剂改善DFS(HR 0.71,95%CI 0.59-0.86),中位DFS未达到 vs 68个月,估计5年DFS率60.9% vs 52.2%。
- 帕博利珠单抗较安慰剂改善OS(HR 0.66,95%CI 0.48-0.90),两组中位OS均未达到,估计5年OS率87.7% vs 82.3%。
- DFS和OS获益在关键亚组中一致,安全性自上次分析以来基本不变。
关键数值与推荐
- DFS:HR 0.71(95%CI 0.59-0.86),中位DFS未达到 vs 68个月,5年DFS率60.9% vs 52.2%。
- OS:HR 0.66(95%CI 0.48-0.90),中位OS均未达到,5年OS率87.7% vs 82.3%。
- 治疗方案:帕博利珠单抗200 mg每3周,≤17个周期(约1年)。
临床怎么用
- 对于复发风险增高的ccRCC患者,肾切除术后或肾切除联合转移灶切除术后可考虑帕博利珠单抗辅助治疗。
- 治疗持续时间≤17个周期(约1年),需关注安全性并与患者沟通获益风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The randomized phase III study KEYNOTE-564 (NCT03142334) established pembrolizumab after surgery as the standard of care for patients with clear cell renal cell carcinoma (ccRCC) at increased risk of recurrence. Prior analyses showed significantly improved disease-free survival (DFS) and overall survival (OS) with adjuvant pembrolizumab versus placebo. We present results from the fourth prespecified interim analysis, with a minimum follow-up of 5 years. PATIENTS AND METHODS: Eligible adults with ccRCC at increased risk of recurrence were randomly assigned 1 : 1 to receive adjuvant pembrolizumab 200 mg or placebo every 3 weeks following nephrectomy or following nephrectomy and metastasectomy. Study treatment continued for ≤17 cycles (∼1 year), until recurrence, or until treatment discontinuation criteria were met. The primary endpoint was DFS per investigator assessment, and the key secondary endpoint was OS. Safety was a secondary endpoint. RESULTS: Overall, 994 participants were randomly assigned to pembrolizumab (n = 496) or placebo (n = 498). Median time from randomization to data cut-off (25 September 2024) was 70 months (range, 60-87). Pembrolizumab improved DFS versus placebo [hazard ratio (HR) 0.71, 95% confidence interval (CI) 0.59-0.86]; median DFS was not reached (NR) versus 68 months, and estimated 5-year DFS rates were 60.9% versus 52.2%, respectively. OS was improved with pembrolizumab over placebo (HR 0.66, 95% CI 0.48-0.90); median OS was NR for both arms with an estimated 5-year OS rate of 87.7% and 82.3%, respectively. DFS and OS benefits were consistent across key subgroups. Safety was largely unchanged since last analysis. CONCLUSIONS: After a median follow-up of 70 months, adjuvant pembrolizumab demonstrated sustained DFS and OS benefit and a safety profile consistent with prior analyses. These findings continue to support the use of adjuvant pembrolizumab in ccRCC at increased risk of recurrence.
引用
- Haas NB, Powles TB, Tomczak P, et al. Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: five-year results from the phase III KEYNOTE-564 study. Ann Oncol. 2026. PMID: 42648402. doi:10.1016/j.annonc.2026.08.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。